Side-by-side · Research reference

Kisspeptin-10vsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/41 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Kisspeptin-10

Neuropeptide · GPR54 Agonist

GnRH pulse generatorPrimary roleSilva 2026

Phase 1/2Clinical stage

GPR54/Kiss1RTarget receptorRønnekleiv 2026

IV / SQ · Investigational

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Kisspeptin-10

Vilon

Primary target

GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026 Collado-Sole 2026

Immune cell differentiation pathways, chromatin modification

Pathway

Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026 Rønnekleiv 2026

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026 Rønnekleiv 2026

Unknown — no HPA/HPG axis data

Origin

C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

Kisspeptin-10

Vilon

Clinical trial dose

Phase 1/2 investigational

Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).

—

Route

IV or SQ administration

IV preferred in controlled trials for precise pulsatile delivery.

Likely SQ or oral (Khavinson school uses both); no published ROA validation

Evidence basis

Phase 1/2 trials

Mouse / in vitro only

Half-life

Short (minutes)

Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.

Not published — dipeptides typically <10 min plasma t½

Standard dose

—

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Frequency

—

Unknown — literature does not specify chronic administration protocols

Duration

—

Not characterised in humans

04Side Effects & Safety

Parameter

Kisspeptin-10

Vilon

Ovarian hyperstimulation

Theoretical risk with supraphysiological dosing in fertility protocols

—

Headache

Mild, reported in early-phase trials

—

Nausea

Transient GI symptoms with IV bolus

—

Hot flashes

Vasomotor symptoms from LH surge

—

Injection site reaction

Erythema, mild discomfort (SQ route)

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Kisspeptin-10

·Active pregnancy
·Hormone-sensitive malignancy (breast, ovarian, endometrial)

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Kisspeptin-10

·Polycystic ovary syndrome (PCOS) without monitoring
·Uncontrolled thyroid dysfunction

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Kisspeptin-10

Vilon

1. Reconstitution (if lyophilized)

Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Route selection

IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Monitoring

Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Storage

Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.

—

06Stack Synergy

Kisspeptin-10

— no documented stacks

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020